60 Degrees Pharmaceuticals (SXTP) Competitors $1.57 -0.06 (-3.91%) As of 10:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock SXTP vs. ALLR, RLYB, MBRX, FBLG, LIXT, SNYR, CLSD, CTXR, CASI, and CINGShould you be buying 60 Degrees Pharmaceuticals stock or one of its competitors? The main competitors of 60 Degrees Pharmaceuticals include Allarity Therapeutics (ALLR), Rallybio (RLYB), Moleculin Biotech (MBRX), FibroBiologics (FBLG), Lixte Biotechnology (LIXT), Synergy CHC (SNYR), Clearside Biomedical (CLSD), Citius Pharmaceuticals (CTXR), CASI Pharmaceuticals (CASI), and Cingulate (CING). These companies are all part of the "pharmaceutical products" industry. 60 Degrees Pharmaceuticals vs. Its Competitors Allarity Therapeutics Rallybio Moleculin Biotech FibroBiologics Lixte Biotechnology Synergy CHC Clearside Biomedical Citius Pharmaceuticals CASI Pharmaceuticals Cingulate Allarity Therapeutics (NASDAQ:ALLR) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership. Do analysts rate ALLR or SXTP? Allarity Therapeutics currently has a consensus price target of $9.25, indicating a potential upside of 442.52%. 60 Degrees Pharmaceuticals has a consensus price target of $3.00, indicating a potential upside of 90.96%. Given Allarity Therapeutics' higher possible upside, equities research analysts clearly believe Allarity Therapeutics is more favorable than 60 Degrees Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.0060 Degrees Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ALLR or SXTP more profitable? Allarity Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -976.86%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Allarity Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Allarity TherapeuticsN/A -173.31% -102.57% 60 Degrees Pharmaceuticals -976.86%N/A -133.88% Does the media favor ALLR or SXTP? In the previous week, 60 Degrees Pharmaceuticals had 3 more articles in the media than Allarity Therapeutics. MarketBeat recorded 5 mentions for 60 Degrees Pharmaceuticals and 2 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 0.96 beat 60 Degrees Pharmaceuticals' score of 0.34 indicating that Allarity Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Allarity Therapeutics Positive 60 Degrees Pharmaceuticals Neutral Do insiders & institutionals have more ownership in ALLR or SXTP? 11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 0.1% of Allarity Therapeutics shares are owned by insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better earnings & valuation, ALLR or SXTP? 60 Degrees Pharmaceuticals has higher revenue and earnings than Allarity Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllarity TherapeuticsN/AN/A-$24.51MN/AN/A60 Degrees Pharmaceuticals$300K21.47-$7.95M-$50.41-0.03 Which has more volatility and risk, ALLR or SXTP? Allarity Therapeutics has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.79, suggesting that its share price is 179% more volatile than the S&P 500. Summary60 Degrees Pharmaceuticals beats Allarity Therapeutics on 6 of the 11 factors compared between the two stocks. Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SXTP vs. The Competition Export to ExcelMetric60 Degrees PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.66M$2.63B$6.12B$10.64BDividend YieldN/A56.68%5.66%4.69%P/E Ratio-0.0323.4986.1127.75Price / Sales21.47640.08588.17183.92Price / CashN/A177.3038.3262.20Price / Book-0.255.5112.976.80Net Income-$7.95M$32.78M$3.30B$275.97M7 Day Performance10.63%3.73%3.27%2.08%1 Month Performance9.86%12.84%10.12%9.09%1 Year Performance-70.08%2.06%83.41%36.72% 60 Degrees Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SXTP60 Degrees Pharmaceuticals2.4748 of 5 stars$1.57-3.9%$3.00+91.0%-69.2%$6.66M$300K-0.033News CoverageAnalyst ForecastALLRAllarity Therapeutics2.4229 of 5 stars$1.75+6.1%$9.25+428.6%+19.7%$23.97MN/A0.0010Analyst ForecastRLYBRallybio3.1218 of 5 stars$0.56-2.4%$5.00+792.9%-50.6%$23.97M$640K-0.6040News CoverageAnalyst ForecastGap DownMBRXMoleculin Biotech3.0975 of 5 stars$0.49+0.6%$4.00+724.7%-79.8%$23.87MN/A0.0020Analyst ForecastFBLGFibroBiologics2.419 of 5 stars$0.49-10.8%$12.67+2,482.9%-81.1%$23.03MN/A0.0010Analyst ForecastHigh Trading VolumeLIXTLixte Biotechnology0.6439 of 5 stars$4.97-1.6%N/A+169.7%$23.03MN/A-3.854Negative NewsAnalyst ForecastSNYRSynergy CHC3.9168 of 5 stars$2.51+3.7%$10.00+298.4%N/A$22.85M$34.83M6.3740Analyst ForecastCLSDClearside Biomedical2.9965 of 5 stars$4.18-3.9%$63.00+1,407.2%-77.8%$22.78M$1.66M-0.7530Positive NewsCTXRCitius Pharmaceuticals2.7215 of 5 stars$1.40+5.3%$53.00+3,685.7%-86.9%$22.63MN/A0.0020Positive NewsAnalyst ForecastHigh Trading VolumeCASICASI Pharmaceuticals4.0207 of 5 stars$1.86+1.6%$4.00+115.1%-66.1%$22.51M$28.54M-0.64180Gap UpCINGCingulate2.5454 of 5 stars$4.15+1.5%$26.25+532.5%+0.2%$22.14MN/A0.0020Analyst Forecast Related Companies and Tools Related Companies ALLR Competitors RLYB Competitors MBRX Competitors FBLG Competitors LIXT Competitors SNYR Competitors CLSD Competitors CTXR Competitors CASI Competitors CING Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SXTP) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network...The Oxford Club | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 60 Degrees Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
